Results 1 to 10 of about 130,251 (209)
Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction [PDF]
Platelets, 2019 The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Amanda J. Unsworth +6 more
doaj +5 more sources
Alexandria Engineering Journal, 2023 Mitogen-activated protein kinase (MEK) inhibitors and oncolytic virotherapy are identified as promising cancer therapies that can enhance the efficacy of other cancer treatments.
M. Moksud Alam +5 more
doaj +1 more source
The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells. [PDF]
PLoS ONE, 2014 Although melanoma is the most aggressive skin cancer, recent advances in BRAF and/or MEK inhibitors against BRAF-mutated melanoma have improved survival rates.
Makoto Wada +4 more
doaj +1 more source
Translational Oncology, 2020 Intrinsic and acquired resistances are major hurdles preventing the effective use of MEK inhibitors for treatment of colorectal cancer (CRC). Some 35–45% of colorectal cancers are KRAS-mutant and their treatment remains challenging as these cancers are ...
Tonći Šuštić +4 more
doaj +1 more source
Epigenetics, 2023 Though DNMTs inhibitors were widely used in myelodysplastic syndrome and leukaemia, their application in solid tumours has been limited by low response rate and lack of optimal combination strategies.
Zhangqian Chen +6 more
doaj +1 more source
A New Compound with Increased Antitumor Activity by Cotargeting MEK and Pim-1
iScience, 2020 Summary: Feedback circuits are one of the major causes underlying tumor resistance. Thus, compounds that target one oncogenic pathway with simultaneously blocking its compensatory pathway will be of great value for cancer treatment.
Yanan Li +10 more
doaj +1 more source
IRF1 Downregulation by Ras/MEK Is Independent of Translational Control of IRF1 mRNA. [PDF]
PLoS ONE, 2016 Oncogenic activation of Ras/MEK downregulates the expression of interferon regulatory factor 1 (IRF1), which is a prerequisite for oncolytic viruses to replicate in cancer cells [1].
Yumiko Komatsu +2 more
doaj +1 more source
Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers. [PDF]
PLoS ONE, 2017 Pancreatic cancer is an increasing cause of cancer related death worldwide. KRAS is the dominant oncogene in this cancer type and molecular rationale would indicate, that inhibitors of the downstream target MEK could be appropriate targeted agents, but ...
Diána Brauswetter +9 more
doaj +1 more source
Case Reports in Gastroenterology, 2022 Encorafenib, a BRAF kinase inhibitor, in combination with binimetinib, a selective MEK inhibitor have known gastrointestinal adverse events; however, adverse colitis events have not been well studied.
Aaron G. Issac +4 more
doaj +1 more source
Cell Death Discovery, 2023 Lipopolysaccharide (LPS) is an endotoxin that can cause an acute inflammatory response. Nitric oxide (NO) is one of the most important innate immune system components and is synthesized by inducible NOS (iNOS) in macrophages in response to stimulation ...
Ryota Hashimoto +2 more
doaj +1 more source